Fibrinogen concentrate to control bleeding in PMP surgery
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This trial tests a medicine called fibrinogen concentrate (CSL511) to see if it helps control bleeding during a special surgery (cytoreductive surgery with HIPEC) for pseudomyxoma peritonei (PMP). The goal is to reduce the need for blood transfusions and improve safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of pseudomyxoma peritonei (a rare cancer in the abdomen) and be scheduled for cytoreductive surgery with HIPEC (a type of surgery with heated chemotherapy).
- Your doctor must expect that you will lose at least 2 liters of blood during the surgery (based on an early assessment).
- You cannot have a known bleeding or clotting disorder.
- You must not have had a heart attack, stroke, or certain other heart problems in the last 2 months.
- You must not have taken certain blood-thinning medications within a specific time before surgery (like clopidogrel, warfarin, or others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
This study tests an investigational treatment called INTERCEPT Fibrinogen Complex (IFC) for people with severe bleeding after a traumatic injury. The treatment helps restore a key blood-clotting protein to try to stop the bleeding and improve survival.
This trial tests whether giving a personalized dose of fibrinogen, a protein that helps blood clot, after heart surgery reduces bleeding and the need for blood transfusions. It aims to improve recovery for patients who need fibrinogen after being on a heart-lung machine.
This trial tests whether giving fibrinogen, a protein that helps blood clot, reduces bleeding during liver transplant surgery. It may help patients with certain liver conditions who are at higher risk of bleeding.
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
Hear when a new Acquired Fibrinogen Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.